Avastin Point/Counterpoint: Hamburg Responds To Genentech’s Arguments On Breast Cancer Claim
Executive Summary
In a point-by-point response, FDA Commissioner Hamburg rebuts Genentech’s many and varied arguments for maintaining bevacizumab’s accelerated approval in first-line metastatic breast cancer.
You may also be interested in...
Avastin Decision Leaves Lingering Uncertainty As To Threshold Level Of Progression-Free Survival Benefit
In her memo revoking Avastin’s metastatic breast cancer claim, FDA Commissioner Hamburg declines to adopt a “bright-line” cutoff of median PFS improvement that would be necessary to establish efficacy, despite industry’s desire for more certainty about the threshold for approval.
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.